ATARA BIOTHERAPEUTICS Reports Q2 FY2023 Earnings Results for June 30 2023
August 17, 2023
🌥️Earnings Overview
On August 8 2023, ATARA BIOTHERAPEUTICS ($NASDAQ:ATRA) released their results for the quarter ending June 30 2023 – compared to the same period in the prior year, total revenue decreased by 98.1%, from USD 18.5 million to USD 1.0 million. Net income was USD -71.1 million, dropping by a whopping USD 89.6 million from the previous year.
Market Price
Atara Biotherapeutics released their quarterly earnings results for the second quarter of fiscal year 2023 on Tuesday. The stock opened for the day at $2.2 and closed at $2.3, up 0.9% from its prior closing price of $2.2. This increase indicates that investors are eager to see what the company has planned for the rest of the year.
The results of the report reflect ATARA BIOTHERAPEUTICS commitment to delivering strong financial performance throughout the remainder of the fiscal year. Investors are encouraged by the financial figures, as they indicate that the company is well-positioned to deliver on its long-term goals. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Atara Biotherapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 6.86 | -304.54 | -4437.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Atara Biotherapeutics. More…
| Operations | Investing | Financing |
| -213.16 | 154.39 | 32.78 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Atara Biotherapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 246.44 | 238.99 | 0.08 |
Key Ratios Snapshot
Some of the financial key ratios for Atara Biotherapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -5160.3% |
| FCF Margin | ROE | ROA |
| -3121.5% | -611.3% | -89.8% |
Analysis
At GoodWhale, we analyze ATARA BIOTHERAPEUTICS’s financials to inform potential investors. Our Risk Rating indicates that ATARA BIOTHERAPEUTICS is a high risk investment in terms of financial and business aspects. If you’re considering investing in ATARA BIOTHERAPEUTICS, we suggest that you take a closer look at their financials. As a registered user, you can access our Risk Report, which details four risk warnings that we have detected in the income statement, balance sheet, cashflow statement and financial journal. We’ve highlighted potential issues with ATARA BIOTHERAPEUTICS’s cash flow, solvency, liquidity and more. This information should help you make an informed decision about whether to invest in ATARA BIOTHERAPEUTICS. More…
Peers
Some of their competitors are Spectrum Pharmaceuticals Inc, Fate Therapeutics Inc, and vTv Therapeutics Inc. All of these companies work to develop new treatments for various diseases and disorders.
– Spectrum Pharmaceuticals Inc ($NASDAQ:SPPI)
Spectrum Pharmaceuticals is a biotechnology company with a focus on developing and commercializing drugs for the treatment of cancer. The company’s market capitalization is $76.43 million, and its return on equity is -154.18%. Spectrum’s products include oral and injectable drugs for the treatment of leukemia, lymphoma, and multiple myeloma. The company also has a pipeline of investigational drugs in development for the treatment of solid tumors.
– Fate Therapeutics Inc ($NASDAQ:FATE)
Fate Therapeutics is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies for cancer and immune disorders. The company’s lead product candidate is ProTmune, a off-the-shelf programmed cellular immunotherapy for the prevention of graft-versus-host disease. The company is also developing immuno-oncology programs, including FT516, a natural killer cell cancer immunotherapy, and FT819, a universal T-cell cancer immunotherapy.
Fate Therapeutics has a market cap of $1.91 billion as of March 2021. The company’s return on equity (ROE) was negative 28.5% for the same period. Fate Therapeutics is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies for cancer and immune disorders. The company’s lead product candidate is ProTmune, a off-the-shelf programmed cellular immunotherapy for the prevention of graft-versus-host disease. The company is also developing immuno-oncology programs, including FT516, a natural killer cell cancer immunotherapy, and FT819, a universal T-cell cancer immunotherapy.
– vTv Therapeutics Inc ($NASDAQ:VTVT)
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of antisense therapeutics. Its marketing products include SPINRAZA, Tegsedi, and Inotersen. The company was founded by Stanley T. Crooke in 1989 and is headquartered in Carlsbad, CA.
Summary
Atara Biotherapeutics reported their second quarter FY2023 earnings on August 8th, with total revenue decreasing from USD 18.5 million to USD 1.0 million, a 98.1% decrease year-over-year. Net income was USD -71.1 million, an increase of USD 89.6 million from the previous year. These figures may not be promising, but investors should consider other metrics when analyzing potential investments in this company. Financial ratios such as operating margin, return on assets and debt-to-equity can provide more insight into the company’s financial health.
Furthermore, the market capitalization and share price should be considered to assess the company’s overall financial performance. Investors should use this information to make informed decisions about investing in Atara Biotherapeutics.
Related Posts
Recent Posts
